NO20054976L - Anvendelse av erytropoietin ved rekonvalens eller slag - Google Patents

Anvendelse av erytropoietin ved rekonvalens eller slag

Info

Publication number
NO20054976L
NO20054976L NO20054976A NO20054976A NO20054976L NO 20054976 L NO20054976 L NO 20054976L NO 20054976 A NO20054976 A NO 20054976A NO 20054976 A NO20054976 A NO 20054976A NO 20054976 L NO20054976 L NO 20054976L
Authority
NO
Norway
Prior art keywords
erythropoietin
reconstitution
stroke
epo
invention demonstrates
Prior art date
Application number
NO20054976A
Other languages
English (en)
Inventor
Kenneth Rhodes
Michael Gold
Michael J Renzi
Navneeth Thirumalai
Francis Farrell
Linda Jolliffe
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20054976L publication Critical patent/NO20054976L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Foreliggende oppfinnelse demonstrerer EPOs effektivitet når det gjelder å fremme pasientrekonvalesens etterfølgende en iskemisk hendelse. Oppfinnelsen demonstrerer at et lenger vindu av muligheter eksisterer når det gjelder den initiale anvendelsen av EPO ved behandling av iskemisk slag i forhold til hva som tidligere har blitt forstått.
NO20054976A 2003-03-27 2005-10-26 Anvendelse av erytropoietin ved rekonvalens eller slag NO20054976L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45819303P 2003-03-27 2003-03-27
US47749403P 2003-06-11 2003-06-11
PCT/US2004/009443 WO2004087063A2 (en) 2003-03-27 2004-03-26 Use of erythropoietin in stroke recovery

Publications (1)

Publication Number Publication Date
NO20054976L true NO20054976L (no) 2005-10-26

Family

ID=33135092

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054976A NO20054976L (no) 2003-03-27 2005-10-26 Anvendelse av erytropoietin ved rekonvalens eller slag

Country Status (11)

Country Link
US (1) US20040209812A1 (no)
EP (1) EP1633383A4 (no)
JP (1) JP2006521405A (no)
AU (1) AU2004226372A1 (no)
BR (1) BRPI0408829A (no)
CA (1) CA2519803A1 (no)
MX (1) MXPA05010345A (no)
NO (1) NO20054976L (no)
NZ (1) NZ542092A (no)
RU (1) RU2341284C2 (no)
WO (1) WO2004087063A2 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
AR036400A1 (es) * 2001-08-30 2004-09-08 Stem Cell Therapeutics Inc Regulacion combinada de la produccion de celulas nerviosas.
ATE541921T1 (de) * 2001-09-14 2012-02-15 Stem Cell Therapeutics Inc Prolaktin-induzierte zunahme an neuronalen stammzellen und dessen therapeutische anwendung
US20030054551A1 (en) * 2001-09-18 2003-03-20 Stem Cell Therapeutics Inc. Effect of growth hormone and IGF-1 on neural stem cells
CA2492442A1 (en) * 2002-07-31 2004-02-05 Stem Cell Therapeutics Inc. Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
BRPI0410470A (pt) * 2003-05-19 2006-06-20 Kenneth S Warren Inst Inc uso de uma eritropoietina ou de uma citocina protetora de tecido e método para proteger ou manter a viabilidade de uma célula, tecido ou órgão de mamìfero respondente
WO2005032467A2 (en) * 2003-09-29 2005-04-14 Warren Pharmaceuticals, Inc. Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
CA2556266A1 (en) 2004-02-13 2005-08-25 Stem Cell Therapeutics Corp. Use of luteinizing hormone (lh), and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis
BRPI0412869A (pt) * 2004-05-20 2006-10-03 Kenneth S Warren Inst Inc uso de uma eritropoietina ou uma citocina protetora de tecido, e, método para proteger ou manter a viabilidade de uma célula, tecido ou órgão mamìferos responsivos
WO2007036033A1 (en) 2005-09-27 2007-04-05 Stem Cell Therapeutics Corp. Oligodendrocyte precursor cell proliferation regulated by prolactin
WO2007106987A1 (en) * 2006-03-17 2007-09-27 Stem Cell Therapeutics Corp. Continuous dosing regimens for neural stem cell proliferating agents and neural stem cell differentiating agents
BRPI0712063A2 (pt) * 2006-06-07 2011-12-20 Chugai Pharmaceutical Co Ltd tratamento de doenças isquêmicas usando eritropoietina
BRPI0921371A2 (pt) * 2008-11-25 2014-11-18 Otsuka Pharmaceutica Co Ltd Células-tronco para uso terapêutico que são derivados de monócito humano, e método para induzir as mesmas.
RU2495688C1 (ru) * 2012-03-28 2013-10-20 Государственное бюджетное учреждение здравоохранения Центр организации специализированной медицинской помощи "Челябинский государственный институт лазерной хирургии" Способ лечения ишемии головного мозга в эксперименте
RU2496513C1 (ru) * 2012-09-27 2013-10-27 Государственное бюджетное учреждение здравоохранения Центр организации специализированной медицинской помощи "Челябинский государственный институт лазерной хирургии" Способ лечения ишемии спинного мозга в эксперименте

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE520730C2 (sv) * 1995-01-20 2003-08-19 Eskil Elmer Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
US6165783A (en) * 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
DE19857609A1 (de) * 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
KR101012932B1 (ko) * 1999-04-13 2011-02-08 더 케네쓰 에스. 워렌 인스티튜트 인코포레이티드 말초 투여된 에리트로포에틴에 의한 흥분조직의 기능조절법
US6784154B2 (en) * 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
BRPI0410470A (pt) * 2003-05-19 2006-06-20 Kenneth S Warren Inst Inc uso de uma eritropoietina ou de uma citocina protetora de tecido e método para proteger ou manter a viabilidade de uma célula, tecido ou órgão de mamìfero respondente

Also Published As

Publication number Publication date
US20040209812A1 (en) 2004-10-21
CA2519803A1 (en) 2004-10-14
WO2004087063A3 (en) 2005-05-19
BRPI0408829A (pt) 2006-04-04
EP1633383A2 (en) 2006-03-15
WO2004087063A2 (en) 2004-10-14
RU2005130023A (ru) 2006-03-20
NZ542092A (en) 2008-04-30
MXPA05010345A (es) 2006-03-08
JP2006521405A (ja) 2006-09-21
AU2004226372A1 (en) 2004-10-14
EP1633383A4 (en) 2008-05-21
RU2341284C2 (ru) 2008-12-20

Similar Documents

Publication Publication Date Title
NO20054976L (no) Anvendelse av erytropoietin ved rekonvalens eller slag
NO20064362L (no) Forbindelser, farmaseutiske sammensetninger og fremgangsmater for anvendelse i behandling av metabolske sykdommer
ECSP088430A (es) Diarilurea para el tratamiento de hipertensión pulmonar
CY1108714T1 (el) Ανταγωνιστες υποδοχεα cgrp
DE60144064D1 (de) Sulfone, die die aktivität von gamma-secretase modulieren
NO20072153L (no) (Bifenyl)-karboksylsyrer og derivater derav
ATE385419T1 (de) Dermatologische und kosmetische zusammensetzungen enthaltend ein furfurylderivat
DE60314495D1 (de) Aminosäuresequenzen die die fähigkeit besitzen, die durchdringung durch eine biologische barriere erleichtern
NO20040100L (no) Nye forbindelser som anti-inflammasjons, immunmodulerende og anti-proliferative midler
NO20062691L (no) Azabicykliske heterocykler som cannabinoide reseptormodulatorer
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
ATE485269T1 (de) C-verknüpfte zyklische antagonisten des p2y1- rezeptors mit eignung bei der behandlung thrombotischer leiden
BR0313676A (pt) Derivados de pirimidina e uso destes como moduladores cb2
ATE368656T1 (de) Piperidinderivate zur verwendung bei der behandlung von durch chemokins vermittelten leiden
ATE356606T1 (de) Juckreizstillende kosmetische und dermatologische zubereitungen
BR0213660A (pt) Composto, composição farmacêutica e método para tratar pacientes
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
EA200801481A1 (ru) 5-(арилсульфонил)пиразолопиперидины
NO20076405L (no) Anvendelse av 24-nor-UDCA
BR0012696A (pt) Composição oftálmica
BRPI0410758A (pt) composições, dispositivos e métodos para estabilizar o dióxido de halogênio e aumentar sua eficácia
ATE340785T1 (de) 2-phenylamino-4-trifluoromethyl-5-(benzyl- oder pyridin-4-ylmethyl)carbamoylpyrimidin-derivate als selektive cb2 cannabinoid-rezeptor modulatoren
EP1682518A4 (en) DIKATIONAL TRIARYLANALOGA AS MEANS AGAINST PROTOZOEN
BRPI0408474A (pt) combinação de amidas de ácidos fenilcarboxìlico com bloqueadores de canal de ikr e uso dos mesmos para tratamento de arritmias do átrio
NO20060420L (no) 2-aminobenzoylderivater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application